Collegium Pharmaceutical, Inc. COLL Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| Belbuca | $52.65M+1.9% | $59.14M+7.1% | $58.26M+9.5% | $52.6M+0.8% | $51.66M+2.0% | |
| Jornay PM | $38.89M+36.3% | $45.89M+56.7% | $41.8M+425% | $32.63M— | $28.54M— | |
| Nucynta ER AG | $1.45M— | —— | —— | —— | $0— | |
| Nucynta ER | $18.23M-7.4% | $18.54M+5.7% | $22.81M+15.4% | $19.95M+3.5% | $19.69M+2.6% | |
| Nucynta IR AG | $1.26M— | —— | —— | —— | $0— | |
| Nucynta IR | $26.08M-4.9% | $29.41M+21.4% | $31.99M+26.1% | $26.5M+5.2% | $27.42M+5.6% | |
| Symproic | $4.19M+49.0% | —— | $4.03M+14.4% | $3.72M-7.7% | $2.82M-14.7% | |
| Xtampza ER | $50.77M+6.6% | —— | —— | —— | $47.64M-0.4% | |
| Finite-Lived Intangible Assets, Net by Product | ||||||
| Belbuca | $56.54M-57.1% | $75.39M-50.0% | $94.24M-44.4% | $113.09M-40.0% | $131.94M-36.4% | |
| Jornay PM | $502.97M-14.3% | $523.93M-13.8% | $544.89M-13.3% | $565.84M— | $586.8M— | |
| Symproic | $40.68M-15.2% | $42.5M-14.6% | $44.32M-14.1% | $46.14M-13.6% | $47.96M-13.2% | |
| Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year by Product | ||||||
| Belbuca | $56.54M0.0% | —— | $18.85M0.0% | $37.69M0.0% | $56.54M0.0% | |
| Jornay PM | $62.87M0.0% | —— | $20.96M0.0% | $41.92M— | $62.87M— | |
| Symproic | $5.46M0.0% | —— | $1.82M+0.3% | $3.64M+0.1% | $5.47M+0.1% | |
| Cost, Amortization by Product | ||||||
| Belbuca | $18.85M0.0% | $18.85M0.0% | $18.85M0.0% | $18.85M0.0% | $18.85M0.0% | |
| Jornay PM | $20.96M0.0% | $20.96M0.0% | $20.96M+233% | $20.96M— | $20.96M— | |
| Symproic | $1.82M0.0% | —— | $1.82M0.0% | $1.82M-0.1% | $1.82M-0.2% | |
| Finite-Lived Intangible Asset, Expected Amortization, Year Four by Product | ||||||
| Belbuca | $0— | $0— | —— | —— | —— | |
| Jornay PM | $83.83M0.0% | $83.83M0.0% | $83.83M0.0% | $83.83M— | $83.83M— | |
| Symproic | $7.29M0.0% | —— | $7.29M0.0% | $7.29M0.0% | $7.29M0.0% | |
| Cost by Product | ||||||
| Belbuca | $360M0.0% | $360M0.0% | $360M0.0% | $360M0.0% | $360M0.0% | |
| Jornay PM | $635M0.0% | $635M0.0% | $635M0.0% | $635M— | $635M— | |
| Symproic | $70M0.0% | $70M0.0% | $70M0.0% | $70M0.0% | $70M0.0% | |
| Finite-Lived Intangible Assets, Accumulated Amortization by Product | ||||||
| Belbuca | $303.46M+33.1% | $284.61M+36.0% | $265.76M+39.6% | $246.91M+44.0% | $228.06M+49.4% | |
| Jornay PM | $132.03M+174% | $111.07M+308% | $90.11M+1,334% | $69.16M— | $48.2M— | |
| Symproic | $29.32M+33.1% | $27.5M+36.0% | $25.68M+39.6% | $23.86M+43.9% | $22.04M+49.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Collegium Pharmaceutical, Inc. break its business down?
- Collegium Pharmaceutical, Inc. (COLL) reports product revenues, net by product across 9 parts — Belbuca, Jornay PM, Nucynta ER AG, Nucynta ER and Nucynta IR AG. Each is extracted from the segment footnotes and tracked over time.
- Where does Collegium Pharmaceutical, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Collegium Pharmaceutical, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
